Herpes Zoster Epidemiology Forecast

DelveInsight's 'Herpes Zoster - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Herpes Zoster epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Herpes Zoster Understanding

The DelveInsight Herpes Zoster epidemiology report gives a thorough understanding of the Herpes Zoster by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Herpes Zoster in the US, Europe, and Japan. The report covers the detailed information of the Herpes Zoster epidemiology scenario in seven major countries (US, EU5, and Japan).


Herpes Zoster Epidemiology Perspective by DelveInsight

The Herpes Zoster epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Herpes Zoster epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Herpes Zoster epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Herpes Zoster Detailed Epidemiology Segmentation

The Herpes Zoster epidemiology covered in the report provides historical as well as forecasted Herpes Zoster epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Herpes Zoster report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Herpes Zoster report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Herpes Zoster Epidemiology Report and Model provide an overview of the risk factors and global trends of Herpes Zoster in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Herpes Zoster in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Herpes Zoster
  • The report provides the segmentation of the Herpes Zoster epidemiology


Report Highlights

  • 11-Year Forecast of Herpes Zoster epidemiology
  • 7MM Coverage
  • Total Cases of Herpes Zoster
  • Total Cases of Herpes Zoster according to segmentation
  • Diagnosed cases of Herpes Zoster


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Herpes Zoster?
  • What are the key findings pertaining to the Herpes Zoster epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Herpes Zoster across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Herpes Zoster?
  • What are the currently available treatments of Herpes Zoster?


Reasons to buy

  • The Herpes Zoster Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Herpes Zoster market
  • Quantify patient populations in the global Herpes Zoster market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Herpes Zoster therapeutics in each of the markets covered
  • Understand the magnitude of Herpes Zoster population by its epidemiology
  • The Herpes Zoster Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Herpes Zoster

3. Herpes Zoster: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Herpes Zoster Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Herpes Zoster Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Herpes Zoster Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Herpes Zoster Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Herpes Zoster Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Herpes Zoster Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Herpes Zoster Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Herpes Zoster Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Herpes Zoster Treatment and Management

6.2. Herpes Zoster Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Herpes Zoster Epidemiology in 7MM (2017-2030)

Table 2 Herpes Zoster Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Herpes Zoster Epidemiology in the United States (2017-2030)

Table 4 Herpes Zoster Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Herpes Zoster Epidemiology in Germany (2017-2030)

Table 6 Herpes Zoster Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Herpes Zoster Epidemiology in France (2017-2030)

Table 8 Herpes Zoster Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Herpes Zoster Epidemiology in Italy (2017-2030)

Table 10 Herpes Zoster Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Herpes Zoster Epidemiology in Spain (2017-2030)

Table 12 Herpes Zoster Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Herpes Zoster Epidemiology in the United Kingdom (2017-2030)

Table 14 Herpes Zoster Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Herpes Zoster Epidemiology in Japan (2017-2030)

Table 16 Herpes Zoster Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Herpes Zoster Epidemiology in 7MM (2017-2030)

Figure 2 Herpes Zoster Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Herpes Zoster Epidemiology in the United States (2017-2030)

Figure 4 Herpes Zoster Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Herpes Zoster Epidemiology in Germany (2017-2030)

Figure 6 Herpes Zoster Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Herpes Zoster Epidemiology in France (2017-2030)

Figure 8 Herpes Zoster Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Herpes Zoster Epidemiology in Italy (2017-2030)

Figure 10 Herpes Zoster Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Herpes Zoster Epidemiology in Spain (2017-2030)

Figure 12 Herpes Zoster Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Herpes Zoster Epidemiology in the United Kingdom (2017-2030)

Figure 14 Herpes Zoster Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Herpes Zoster Epidemiology in Japan (2017-2030)

Figure 16 Herpes Zoster Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Herpes Zoster Epidemiology
  • Herpes Zoster
  • Herpes Zoster Pipeline
  • Herpes Zoster Companies
  • Herpes Zoster prevalent population
  • Herpes Zoster incident population
  • Herpes Zoster patients diagnosed
  • Herpes Zoster treatment algorithm

Forward to Friend

Need A Quote